Chimeric antigen receptor T-cell (CAR-T) therapy targeting the MUC1* receptor, binding site for a crucial growth factor MUC1 which is masked on healthy tissue. Hence it can specifically stop a tumor from growing without targeting the healthy cells. The CAR-T therapy was designated initially for blood cancer of B-cell type mainly, as B-cell equivalent targets in solid tumours are yet to be found before this approach was developed. MUC1* is expressed aberrantly in 95% of breast cancers, 83% of ovarian cancers, 78% of pancreatic cancers, and 71% of lung cancers which is the B-cell equivalent in solid tumors.

For more information: